



Published in final edited form as:

Int J Obes Suppl. 2012 ; 2: S7–S13. doi:10.1038/ijosup.2012.15.

The Impact of Maternal High-Fat Diet Consumption on Neural Development and Behavior of Offspring

Elinor L. Sullivan^{a,b}, Elizabeth K. Nousen^a, Katherine A. Chamlou^a, and Kevin L. Grove^b

^aDepartment of Biology, University of Portland, Portland, OR, USA

^bDivision of Neuroscience, Oregon National Primate Research Center, Beaverton, OR, USA

Abstract

Maternal diet and metabolic state are important factors in determining the environment experienced during perinatal development. Epidemiological studies and evidence from animal models provide evidence that a mother's diet and metabolic condition are important in programming the neural circuitry that regulates behavior, resulting in a persistent impact on the offspring's behavior. Potential mechanisms by which maternal diet and metabolic profile influence the perinatal environment include placental dysfunction and increases in circulating factors such as inflammatory cytokines, nutrients (glucose and fatty acids) and hormones (insulin and leptin). Maternal obesity and high-fat diet (HFD) consumption exposure during development have been **observed to increase the risk of developing serious mental health and behavioral disorders including anxiety, depression, attention deficit hyperactivity disorder and autism spectrum disorder**. The increased risk of developing these behavioral disorders is postulated to be due to perturbations in the development of neural pathways that regulate behavior, including the serotonergic, dopaminergic and melanocortinergic systems. It is critical to examine the influence that a mother's nutrition and metabolic profile have on the developing offspring considering the current and alarmingly high prevalence of obesity and HFD consumption in pregnant women.

Keywords

maternal high fat diet; anxiety; depression; inflammation; placental dysfunction; autism spectrum disorders; attention deficit hyperactivity disorder

Introduction

Obesity has a significant and deleterious effect on numerous aspects of human health. Being obese increases the risk of many serious diseases including cardiovascular disease, hypertension, diabetes and several forms of cancers (1–3). Mounting evidence suggests that obesity is also associated with mental health disorders such as anxiety (4), depression (4) and attention deficit hyperactivity disorder (ADHD) (5). As obesity increases the risk of many serious metabolic diseases and behavioral disorders, it has a significant impact on quality of life and decreases life expectancy. According to the latest statistics from the

Corresponding author: Elinor L. Sullivan, PhD, University of Portland, 5000 N. Willamette Blvd., Portland, OR 97203, sullivae@up.edu, (503) 943-8861 (phone), (503) 943-7784 (fax).

National Health and Nutrition Examination Survey, a third of adult Americans are currently obese (6). The prevalence of obesity in both adults and children has markedly increased in the United States over the past three decades (7); childhood obesity has more than tripled in children aged 6–11 years since 1980 (8). The recent dramatic rise in the prevalence of obesity has led to a staggering increase in national health-care costs. This surge in obesity rates is likely due in part to increased accessibility to calorically dense and highly palatable foods (9). In addition, modern technologies have decreased the amount of energy needed to complete daily tasks, and adults and children are increasingly able to choose sedentary activities such as watching television and playing video games in place of more physically active leisure activities (9). Of dire concern, recent reports and news in the popular press have suggested that the current new generation will be the first to have a decreased life expectancy compared to their parents (10, 11). Importantly, there is increasing evidence from animal models that programming during perinatal environment contributes to the striking rise in obesity rates (12–15).

Although there are many aspects by which maternal obesity, insulin resistance and/or diet affect fetal and adolescent development, this review will focus on the critical impact on brain development that has consequences for offspring behavior. It is our belief that negative impacts on behavior and increased risks of psychiatric disorders may have a consequence on quality of life as serious as the potential metabolic outcomes that impact life expectancy.

Maternal Obesity Increases Offspring's Risk of Obesity and Metabolic Diseases

A third of pregnant American women are currently obese (8), and the majority consume excess calories due to consumption of a diet high in fat (16). Children who are exposed to maternal obesity during gestation have an increased risk of obesity and metabolic syndrome in adulthood (17, 18). Furthermore, gestational diabetes, which can significantly affect prenatal development, has also been well documented to increase offspring risk of adult obesity (19). The effect of maternal obesity on the susceptibility to obesity in offspring is thought to be independent of gestational diabetes because obese mothers with euglycemia still have babies with increased adiposity (20). Maternal obesity also increases the risk of the child developing fatty liver disease, cardiovascular disease and diabetes (8, 21). Given the high prevalence of obesity in pregnant women, it is critical to examine the full impact of maternal obesity on the developing offspring.

However, it should be noted that one of the limiting factors of the human studies is the inability to segregate the possible effects of the maternal metabolic phenotype versus the diet that may be causing the obesity and insulin resistance. To truly understand the relative contributions of the different aspects of metabolic complications associated with maternal obesity, we need to have better characterization of the metabolic phenotype and diet in these clinical and epidemiological studies. Much can also be learned from well-controlled animal models.

Animal Models of Maternal Obesity

Maternal obesity is commonly simulated in animal models by feeding adult females a palatable diet that is high in fat. However, the duration of diet exposure and the composition of the diet are variable between studies. The diets most often used to produce obesity are either a refined high-fat diet (HFD) with fat in place of carbohydrates as an energy source or a cafeteria diet in which animals are provided with a selection of calorie-dense palatable food items that have a high fat and carbohydrate content along with their regular diet. The cafeteria diet is most effective in promoting obesity possibly because of the greater caloric load and/or increased consumption of carbohydrates. Differences between studies may be partly due to the carbohydrate content of the diet, as perinatal high carbohydrate consumption has been shown to have a lasting impact on neural development in rodent (22) and sheep (23) models. Rats fed a HFD through pregnancy and lactation have pups with increased body weight and adiposity, as well as higher rates of hyperglycemia compared to pups from control diet-fed mothers (24). Murine models of chronic maternal overnutrition also find that offspring show increased adiposity due to hyperphagia and reduced locomotor activity (25). In addition, exposure to a highly palatable junk-food diet during perinatal development results in offspring with increased preference for fatty, sugary and salty foods (26). Our group has further confirmed these findings using a nonhuman primate (NHP) model of HFD-induced maternal obesity. Juvenile offspring from HFD-fed mothers display increased body weight and fat mass, hyperleptinemia, and the early stages of fatty liver disease (27). Importantly, we demonstrated that the effects of maternal HFD on the offspring are independent of maternal obesity (27). These studies confirm that in animal models, maternal overnutrition predisposes offspring to early-onset obesity and metabolic disorders. Since these maternal HFD effects are independent of obesity (27), it may be critical to provide nutritional advice to all pregnant women and not just those who are visibly obese.

Maternal Obesity Increases Offspring's Risk of Mental Health Disorders

In recent years, maternal obesity has also been linked to increased risk of behavioral disorders in human offspring, including ADHD (28, 29) and autism spectrum disorders (ASD) (30). Maternal obesity and diabetes are also linked with an increased prevalence of ASD and developmental delays in children aged 2–5 years old (30). Mothers of children with ADHD are almost twice as likely to be obese than mothers of unaffected children (28). Similarly, pre-pregnancy obesity is associated with a twofold risk in ADHD symptom score in offspring, compared with the children of women who were of normal weight during pregnancy (29). Children of mothers with maternal diabetes also showed significant deficits in expressive language (30). These human studies indicate a potential link between having an obese mother and developing behavioral disorders, but it is unclear if this relationship is due to genetic factors, a common postnatal environment, or the prenatal environment that offspring from obese mothers experience due to diet. Animal studies have begun to shed some light on the contribution of each of these important factors.

Animal Models of Maternal Obesity Show Persistent Behavioral Changes

Animal studies provide clear evidence that offspring behavior is affected by maternal HFD consumption. Recent studies in NHP (31) and rodent (32) models indicate that maternal HFD consumption is associated with increased anxiety. Adult male rat offspring exposed to a diet high in either saturated or trans fat during gestation and lactation displayed increased anxiety (32). However, other studies in rodents suggest that HFD feeding decreases anxiety. It appears that this may be dependent on the composition of the diet and on the timing of consumption (33) by the mother. Offspring from mothers fed a purified HFD throughout the perinatal period displayed increased anxiety, whereas offspring exposed to a cafeteria diet during lactation displayed evidence of decreased anxiety (33). Moreover, cafeteria diet consumption during the early postnatal period has been observed to reduce anxiety and depression-like behaviors in rodent offspring exposed to stress during gestation (34). By using a NHP model, our group demonstrated that maternal HFD consumption through the perinatal period suppresses serotonergic system signaling, which predisposes female offspring to increased anxiety (31). The finding that female NHP offspring exposed to maternal HFD consumption are more sensitive to developing anxiety than male offspring is consistent with findings in humans that indicate that females are more susceptible to anxiety than males and that the association between obesity and anxiety is stronger in women than men (35). However, the studies in the animal models suggest that there could be an earlier programming event that causes a neurochemical imbalance that makes these individuals especially sensitive to social stresses later in life.

Indeed, maternal diet during the perinatal period also impacts the offspring's social behavior. Rat offspring exposed to a maternal diet high in polyunsaturated fatty acids displayed increased aggression to intruders (36). Changes in reward-based feeding have also been observed in several models of maternal HFD consumption (26, 37, 38). For example, rat offspring exposed to junk food during either gestation or lactation displayed increased preference for fatty, sugary and salty foods as adults (26, 37, 38). This finding is confirmed by preliminary studies using our NHP model of HFD-induced maternal obesity, which find that HFD offspring display increased preference for diets with a high sugar and fat content (Sullivan and Grove, unpublished observation). Maternal HFD consumption has also been associated with decreased behavioral sensitization to amphetamine in the offspring by altering dopamine transmission through the nucleus accumbens (39). These studies provide compelling evidence that perinatal nutrition may have a long-term influence on reward-based behaviors such as consumption of palatable food and response to drugs of abuse.

Potential Mechanisms for Maternal Obesity Programming Behavior

Several mechanisms are postulated to be contributors to the impact that maternal obesity and HFD consumption have on the development of the complex neural circuitry involved in behavioral regulation. HFD exposure has been observed to affect the development of neurotransmitter signaling pathways such as the serotonergic (31), dopaminergic (39, 40), melanocortinergic (41), and galanin systems (42). Maternal obesity and HFD consumption are associated with a number of potential factors that can affect brain development: placental

dysfunction, increased exposure to inflammatory factors, increased circulating levels of metabolic hormones, and increased levels of nutrients.

Maternal Obesity Causes Placental Dysfunction

The increased rate of maternal obesity in humans corresponds with an increase in pregnancy complications (18). These complications are thought to be due to placental dysfunction, as placental dysfunction has been observed in NHP (43) and ovine models (44) of maternal obesity and HFD consumption. Studies with large animal models indicate that there is a strong association between maternal diet and disruption of normal placental function. Our group has demonstrated that NHP mothers that consumed a HFD before and during pregnancy showed a 35–50% decrease in uterine artery blood flow, which was independent of maternal metabolic phenotype (43). There were further complications with fetal blood flow and a higher frequency of placental infarctions and stillbirths if the mothers were obese and insulin resistant (43). Ovine studies similarly found that overnourished ewes exhibited decreased uterine blood flow, a reduction in placental mass by one third and reduced placental capillary density (44). Rodent models of maternal HFD consumption have also shown reduced placental mass (45). These findings emphasize that there is a consistent relationship between HFD consumption and reduced uterine blood flow (44), leading to placental dysfunction.

Maternal Obesity is Associated with Inflammation

Obesity can be thought of as a state of chronic inflammation because it results in increased levels of circulating inflammatory cytokines in many organs, including the brain (46) and the placenta (47, 48). In human studies, the amount of adipose tissue mass is positively correlated with elevations in markers of inflammation such as C-reactive protein, interleukin (IL)-6, and IL-1 β in the plasma (46, 49). These inflammatory markers are associated with an increased risk for a number of metabolic diseases: cardiovascular disease, heart disease, insulin resistance, type 2 diabetes mellitus and hypertension (46). In patients with type 1 diabetes, who suffer from a compromised immune system, metabolic disease is associated with increased serum levels of the endotoxin lipopolysaccharide (LPS) originating from bacterial colonization of the gastrointestinal tract (50). LPS upregulates inflammatory responses through pathways modulated by receptors such as toll-like receptor-4 (51). During pregnancy, increased levels of inflammatory cytokines secreted from adipocytes in obese women contribute to endothelial (52) and placental dysfunction (53). As maternal obesity can stimulate endotoxemia and elevated inflammatory cytokines, it increases the amount of inflammatory factors that the developing fetus comes into contact with and that affects neural development.

HFD-Induced Inflammation Results in Placental Dysfunction in Animal Models

As described above, maternal obesity and HFD consumption are associated with both decreased placental blood flow and an increase in circulating inflammatory cytokines. In addition, evidence from animal models indicates that consumption of a HFD increases

inflammation in the placenta. The placentae of obese sheep displayed elevated levels of activated inflammatory signaling pathways and inflammatory cytokine activity compared with those of nonobese ewes (54). Furthermore, in our NHP model, we have shown that consumption of a HFD, regardless of the metabolic state of the mother, increases the expression of placental inflammatory cytokines and that these cytokines are selectively secreted into the fetal compartment (43). This is of grave concern, as rodent models have shown that placentally generated cytokines initiated further cytokine synthesis in the fetus, perpetuating the inflammatory environment (55, 56). Elevation of such cytokines also led to changes in growth factors that are essential for fetal development (57) and for changes in behavior.

Inflammation-Induced Neural Programming

There is strong evidence that exposure to increased circulating cytokines during fetal development affects brain development and thus is a potential mechanism by which maternal HFD consumption affects behavioral regulation. Rodent offspring from mothers consuming a HFD exhibit neural inflammation as evidenced by increased microglial activation in the hippocampus, which persists into adulthood (57) and is associated with decreased neurogenesis in the corresponding region (58). NHP offspring from mothers consuming a HFD show an increase in circulating and hypothalamic cytokines during the early third trimester (41). The development of neurotransmitter systems critical for regulating behavior are affected by such circulating cytokines (46). This exposure to increased inflammatory cytokines may lead to the perturbations in the melanocortinergic (41) and serotonergic system observed in fetal offspring (31). Maternal HFD consumption downregulates dopamine release in the nucleus accumbens of rodent offspring, leading to increased motivation to consume fatty food (40). Rats that had decreased accumbens dopamine were more likely to be obese (59), indicating that they may be increasing consumption in order to combat their lower levels of dopamine. Palatable food may therefore be overconsumed in an attempt to elevate dopamine levels. One study suggests that increasing consumption of fatty foods causes a positive feedback loop in the nucleus accumbens and hippocampus, meaning that increases in palatable food intake would increase the desire of an individual to eat fatty food (60).

Neural inflammation has also been observed as a result of bacterial or viral infection, and this evidence demonstrates how influential inflammation is for brain development. It is well documented that when infections or illness occur during pregnancy, there is a subsequent increase in inflammatory cytokines delivered to the developing fetus, which in turn causes an inflammatory response in the fetal brain during critical periods of development (61). For example, women who were infected with influenza during pregnancy had offspring who were at an increased risk of developing schizophrenia (62). NHP studies show that a mid-gestational influenza infection results in atypical brain development similar to what is seen in cases of schizophrenia, such as reduced cortical gray matter and enlarged lateral ventricles (63, 64). These structural abnormalities are persistent and are likely to manifest into behavioral dysfunction, but this study was not long enough to observe the full extent of behavioral effects (64). Offspring of NHP mothers affected by influenza during pregnancy demonstrated trouble with attention and orientation tasks from an early age (64). Recent

evidence indicates that gestational obesity may have an effect similar to gestational infection or illness, as it also elevates the levels of inflammatory cytokines that a fetus is exposed to (43). Therefore, maternal obesity may similarly impact neural development, increasing the risk for behavioral disorders and metabolic diseases. These data demonstrate that the disruptions caused by inflammatory cytokines after infection may be similar to what is seen after maternal HFD consumption, extending beyond placental compromise into fetal brain development and offspring behavior.

Human Inflammation and Behavioral Abnormalities

Exposure to elevated maternal inflammatory cytokines has been indicated to have a role in human fetal brain development and consequently have a persistent impact on behavior. A number of psychopathologies, including Alzheimer's disease (65), anxiety (66–68), depression (69–71), ASD (72–74), and ADHD (75), have been linked with exposure to inflammatory cytokines. When proinflammatory cytokines cross the placenta and enter the fetal bloodstream, the fetal brain undergoes excessive neuronal growth and plasticity, termed a 'cytokine-storm' (76). Buehler (76) proposes that the inundation of cytokines and the subsequent neuronal growth can in turn assist the development of a state of chronic inflammation in the fetal environment and that this may explain many of the symptoms observed in individuals with ASD. Symptoms of ASD including hypersensitivity to external stimuli, repetition of heard sounds and movements, and object fixation are postulated to be a result of this mechanism (76). HFD consumption during pregnancy has been shown to activate many of the same inflammatory cytokines that have been reported to be elevated either during gestation in mothers of children that developed ASD such as IL-4 and IL-5 (72) or in children with ASD including monocyte chemoattractant protein-1, RANTES, and granulocyte-macrophage colony-stimulating factor (73, 74). In addition, *in utero* exposure to high levels of IL-8 results in fetal brain alterations that are consistent with the neurological structure of schizophrenia patients (77), and thus the elevation of this cytokine in response to maternal obesity could increase the risk of schizophrenia in offspring from obese mothers. Studies that focused on obesity instead of on its consequent inflammatory response also show a link between obesity and behavioral disorders. These mechanisms propose that inflammatory cytokines and obesity affect human brain development in a way that leads to the development of behavioral abnormalities.

Psychopathologies as Pro-Inflammatory Responses

The increased cytokine reactivity stimulated by intrauterine infection or maternal HFD consumption can be induced by administration of proinflammatory factors, further corroborating that inflammation is a mechanism responsible for the consequent alterations in fetal brain development (56, 78, 79). Injection of LPS elicits increased cytokine reactivity in infant monkeys (78) and caused systemic inflammation in cats (80) and horses (81). NHP infants from high LPS pregnancies demonstrated behavior that contained disturbances similar to what is seen in ASD and schizophrenia, such as the failure to exhibit a normal startle response (78). These LPS infants displayed reduced gray matter (78), which is similarly seen in NHP models of perinatal influenza (64), and also had a significant 8.8% increase in white matter volume across many cortical regions (78), which is similar to the

increased white matter growth seen in the early development of individuals with ASD (82, 83). Offspring of rats fed a HFD had heightened response to LPS compared with controls, and these rats also displayed alterations in anxiety and spatial learning (32). These studies of endotoxemia indicate that elevated levels of inflammatory cytokines, whether triggered by HFD consumption or infection, create a pathway that affects the development of the neurocircuitry in ways that are consistent to the neural abnormalities observed in human psychopathologies.

As exposure to inflammation during development causes a nonspecific response that impacts many neurotransmitter systems, it is important for future research to directly examine the influence of maternal obesity and HFD consumption-induced inflammation on each neural pathway important in behavioral regulation. Compounds with anti-inflammatory properties, such as ursolic acid, have been found to improve the behavioral performances of mice fed a HFD (84). This cognitive improvement was credited to the inhibition of inflammatory signaling and suggests that anti-inflammatory agents may be helpful in combating obesity-induced cognitive impairments (84).

Programming by Excess Hormones and Nutrients

Maternal Obesity is Associated with Gestational Diabetes—As maternal obesity is often associated with gestational diabetes (85), rates of gestational diabetes will continue to increase as the obesity epidemic continues. Gestational diabetes is associated with the initiation of inflammation in the placenta (47–49), and thus the same mechanisms responsible for placental dysfunction in intrauterine infection and HFD consumption are also activated by gestational diabetes (86). Both human and rodent models point to the placenta as one target of the negative effects of maternal diabetes (87). Gestational diabetes is linked with hyperglycemia and hyperinsulinemia (88). The fetus is only exposed to higher levels of glucose because glucose, but not insulin, can permeate through the blood-placenta barrier and be transferred to the fetus (89). The fetal pancreas compensates for this hyperglycemia by increasing insulin release. As insulin is an important neural growth factor (90), it is proposed that early exposure to hyperinsulinemia alters the development of brain circuitry regulating energy balance and behavior. This theory is supported by studies that find that insulin administration during the last term of gestation alters energy balance and produces obese offspring (91, 92) and that administering insulin to the hypothalamus of rat pups during the time that projections from the arcuate nucleus (ARH) to the paraventricular nucleus (PVH) are developing results in elevations in body weight and insulin level, impaired glucose tolerance and increased vulnerability to diabetes in adulthood (93).

Maternal Obesity is Associated with Hyperleptinemia—Leptin is a satiety factor secreted by adipocytes in proportion to the amount of fat mass, and, consequently, offspring from obese mothers are exposed to increased levels of leptin. The hyperleptinemia that offspring from obese mothers experience during development is implicated in metabolic imprinting. There is substantial evidence in rodents that postnatal leptin is a critical factor in the development of neural pathways in the hypothalamus (94–96). In addition, offspring from rodent mothers who consumed a HFD and had increased circulating leptin levels showed increased inflammation in the periphery and hypothalamus, even if they consumed a

healthy diet after birth (32). Rodent studies indicate that neonatal overnutrition increases postnatal leptin resistance in the arcuate nucleus (97), leading to overconsumption of palatable foods (96, 97). Human studies report that leptin is elevated in obese (98) and diabetic mothers (99, 100) and is lower in infants who experienced intrauterine growth restriction at term (101). However, in human and NHP gestation, circulating leptin levels do not increase until after hypothalamic development is well advanced (102, 103). Although critical for brain development in rodents, there is limited evidence for leptin's role in the development of primate brains (97, 104). Yet, hyperleptinemia is associated with placental dysfunction (98, 99), and thus elevated leptin may impact brain development indirectly. Hyperleptinemia may also result from the effect that maternal HFD has on the leptin signaling pathway. Offspring from HFD mothers experienced reduced phospho-signal transducer and activator of transcription-3 activation as compared with control pups (97). This suggests that leptin resistance develops during the suckling period and persists through life, increasing the susceptibility of HFD offspring to obesity (97). To date, studies examining the role of leptin in influencing the development of neural pathways that regulate behavior have focused on feeding behavior (105, 106); however, with the increasing evidence that maternal metabolic state influences social and mental health behavior in offspring, future studies will work to determine the role that leptin has in programming mental health-related behavior.

Maternal HFD-Induced Suppression of the Serotonin System—The serotonin (5-HT) system has an integral role in neural development, influencing neurogenesis, neuronal migration and synaptogenesis (107, 108). Furthermore, the metabolism of tryptophan (TRP), the precursor to 5-HT, through the kynurenine (KYN) pathway has a crucial role in immune function during pregnancy. During the first trimester, metabolism of TRP prevents the rejection of the fetus by suppressing the maternal immune response (109), and it is involved in the regulation of blood flow between the placenta and fetus during the second and third trimesters of gestation (110). KYN metabolites have been reported to be elevated in animal models of maternal inflammation (111). As the KYN pathway competes with 5-HT for the substrate TRP, an increase in the KYN pathway results in less TRP availability for 5-HT synthesis. As mentioned previously, our group has demonstrated that chronic consumption of a HFD during pregnancy reduces placental blood flow, indicating the potential role of the elevated KYN levels; however, this effect is further exacerbated if the animals are obese and insulin resistant (43). Furthermore, in humans, a suppression of brain 5-HT synthesis is associated with a number of mental health and behavioral disorders like anxiety (112), depression (113), ADHD (114) and ASD (115), and thus perturbations in the 5-HT system are postulated to underlie the increased risk of offspring exposed to maternal overnutrition developing behavioral disorders.

Conclusion

In summary, there are several mechanisms by which maternal obesity and HFD consumption may affect the developing fetal brain and thus behavioral regulation. These mechanisms include placental dysfunction, the increased exposure to inflammatory cytokines and the higher levels of nutrients and metabolic hormones that offspring receive

from obese mothers. The serotonergic system has been identified as a potential mediator of maternal HFD-induced behavioral dysregulation, and suppression in the 5-HT system has been documented in several different animal models. With the current prevalence of maternal HFD consumption and obesity, future generations are at an increased risk for behavioral and mental health disorders. Given the high rates of maternal obesity, future studies need to identify therapeutic strategies that are effective at preventing maternal HFD-induced malprogramming of offspring behavior.

References

1. Krauss RM, Eckel RH. The obesity problem. *The New England journal of medicine*. 1998; 338:1156. author reply 1158. [PubMed: 9547143]
2. Hossain P, Kavar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. *The New England journal of medicine*. 2007; 356:213–215. [PubMed: 17229948]
3. Haslam DW, James WP. Obesity. *Lancet*. 2005; 366:1197–1209. [PubMed: 16198769]
4. Rofey DL, Kolko RP, Iosif AM, Silk JS, Bost JE, Feng W, Szigethy EM, Noll RB, Ryan ND, Dahl RE. A longitudinal study of childhood depression and anxiety in relation to weight gain. *Child psychiatry and human development*. 2009; 40:517–526. [PubMed: 19404733]
5. Waring ME, Lapane KL. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample. *Pediatrics*. 2008; 122:e1–6. [PubMed: 18595954]
6. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *JAMA*. 2012; 307:491–497. [PubMed: 22253363]
7. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. *JAMA*. 2012; 307:483–490. [PubMed: 22253364]
8. King JC. Maternal obesity, metabolism, and pregnancy outcomes. *Annu Rev Nutr*. 2006; 26:271–291. [PubMed: 16704347]
9. Finkelstein EA, Ruhm CJ, Kosa KM. Economic causes and consequences of obesity. *Annual review of public health*. 2005; 26:239–257.
10. Catenacci VA, Hill JO, Wyatt HR. The obesity epidemic. *Clinics in chest medicine*. 2009; 30:415–444. vii. [PubMed: 19700042]
11. Daniels SR. The consequences of childhood overweight and obesity. *The Future of children/Center for the Future of Children, the David and Lucile Packard Foundation*. 2006; 16:47–67.
12. Vickers MH, Gluckman PD, Coveny AH, Hofman PL, Cutfield WS, Gertler A, Breier BH, Harris M. Neonatal leptin treatment reverses developmental programming. *Endocrinology*. 2005; 146:4211–4216. [PubMed: 16020474]
13. Yura S, Itoh H, Sagawa N, Yamamoto H, Masuzaki H, Nakao K, Kawamura M, Takemura M, Kakui K, Ogawa Y, Fujii S. Role of premature leptin surge in obesity resulting from intrauterine undernutrition. *Cell metabolism*. 2005; 1:371–378. [PubMed: 16054086]
14. Sullivan EL, Smith MS, Grove KL. Perinatal exposure to high-fat diet programs energy balance, metabolism and behavior in adulthood. *Neuroendocrinology*. 2011; 93:1–8. [PubMed: 21079387]
15. Sullivan EL, Grove KL. Metabolic imprinting in obesity. *Forum of nutrition*. 2010; 63:186–194. [PubMed: 19955786]
16. Alberti-Fidanza A, Parizkova J, Fruttini D. Relationship between mothers' and newborns' nutritional and blood lipid variables. *European journal of clinical nutrition*. 1995; 49:289–298. [PubMed: 7796787]
17. Vickers MH, Breier BH, Cutfield WS, Hofman PL, Gluckman PD. Fetal origins of hyperphagia, obesity, and hypertension and postnatal amplification by hypercaloric nutrition. *Am J Physiol Endocrinol Metab*. 2000; 279:E83–87. [PubMed: 10893326]
18. Aimukhmetova G, Ukybasova T, Hamidullina Z, Zhubanysheva K, Harun-Or-Rashid M, Yoshida Y, Kasuya H, Sakamoto J. The impact of maternal obesity on mother and neonatal health: study in

a tertiary hospital of Astana, Kazakhstan. *Nagoya journal of medical science*. 2012; 74:83–92. [PubMed: 22515114]

19. Gillman MW, Rifas-Shiman S, Berkey CS, Field AE, Colditz GA. Maternal gestational diabetes, birth weight, and adolescent obesity. *Pediatrics*. 2003; 111:e221–226. [PubMed: 12612275]
20. Sewell MF, Huston-Presley L, Super DM, Catalano P. Increased neonatal fat mass, not lean body mass, is associated with maternal obesity. *Am J Obstet Gynecol*. 2006
21. Kunz LH, King JC. Impact of maternal nutrition and metabolism on health of the offspring. *Seminars in fetal & neonatal medicine*. 2007; 12:71–77. [PubMed: 17200031]
22. Patel MS, Srinivasan M. Metabolic programming in the immediate postnatal life. *Annals of nutrition & metabolism*. 2011; 58(Suppl 2):18–28. [PubMed: 21846978]
23. Muhlhauser BS, Adam CL, Findlay PA, Duffield JA, McMillen IC. Increased maternal nutrition alters development of the appetite-regulating network in the brain. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2006; 20:1257–1259. [PubMed: 16684802]
24. Guo F, Jen KL. High-fat feeding during pregnancy and lactation affects offspring metabolism in rats. *Physiology & behavior*. 1995; 57:681–686. [PubMed: 7777603]
25. Samuelsson AM, Matthews PA, Argenton M, Christie MR, McConnell JM, Jansen EH, Piersma AH, Ozanne SE, Twinn DF, Remacle C, Rowlerson A, Poston L, Taylor PD. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: a novel murine model of developmental programming. *Hypertension*. 2008; 51:383–392. [PubMed: 18086952]
26. Bayol SA, Farrington SJ, Stickland NC. A maternal ‘junk food’ diet in pregnancy and lactation promotes an exacerbated taste for ‘junk food’ and a greater propensity for obesity in rat offspring. *The British journal of nutrition*. 2007; 98:843–851. [PubMed: 17697422]
27. McCurdy CE, Bishop JM, Williams SM, Grayson BE, Smith MS, Friedman JE, Grove KL. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. *J Clin Invest*. 2009; 119:323–335. [PubMed: 19147984]
28. Ray GT, Croen LA, Habel LA. Mothers of children diagnosed with attention-deficit/hyperactivity disorder: health conditions and medical care utilization in periods before and after birth of the child. *Medical care*. 2009; 47:105–114. [PubMed: 19106738]
29. Rodriguez A, Miettunen J, Henriksen TB, Olsen J, Obel C, Taanila A, Ebeling H, Linnet KM, Moilanen I, Jarvelin MR. Maternal adiposity prior to pregnancy is associated with ADHD symptoms in offspring: evidence from three prospective pregnancy cohorts. *International journal of obesity*. 2008; 32:550–557. [PubMed: 17938639]
30. Krakowiak P, Walker CK, Bremer AA, Baker AS, Ozonoff S, Hansen RL, Hertz-Picciotto I. Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. *Pediatrics*. 2012; 129:e1121–1128. [PubMed: 22492772]
31. Sullivan EL, Grayson B, Takahashi D, Robertson N, Maier A, Bethea CL, Smith MS, Coleman K, Grove KL. Chronic consumption of a high-fat diet during pregnancy causes perturbations in the serotonergic system and increased anxiety-like behavior in nonhuman primate offspring. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2010; 30:3826–3830. [PubMed: 20220017]
32. Bilbo SD, Tsang V. Enduring consequences of maternal obesity for brain inflammation and behavior of offspring. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2010; 24:2104–2115. [PubMed: 20124437]
33. Wright T, Langley-Evans SC, Voigt JP. The impact of maternal cafeteria diet on anxiety-related behaviour and exploration in the offspring. *Physiol Behav*. 2011; 103:164–172. [PubMed: 21241725]
34. Maniam J, Morris MJ. Palatable cafeteria diet ameliorates anxiety and depression-like symptoms following an adverse early environment. *Psychoneuroendocrinology*. 2010; 35:717–728. [PubMed: 19939573]
35. Desai RA, Manley M, Desai MM, Potenza MN. Gender differences in the association between body mass index and psychopathology. *CNS Spectr*. 2009; 14:372–383. [PubMed: 19773713]

36. Raygada M, Cho E, Hilakivi-Clarke L. High maternal intake of polyunsaturated fatty acids during pregnancy in mice alters offsprings' aggressive behavior, immobility in the swim test, locomotor activity and brain protein kinase C activity. *J Nutr.* 1998; 128:2505–2511. [PubMed: 9868200]
37. Walker CD, Naef L, d'Asti E, Long H, Xu Z, Moreau A, Azeddine B. Perinatal maternal fat intake affects metabolism and hippocampal function in the offspring: a potential role for leptin. *Ann N Y Acad Sci.* 2008; 1144:189–202. [PubMed: 19076377]
38. Nakashima Y. Fish-oil high-fat diet intake of dams after day 5 of pregnancy and during lactation guards against excessive fat consumption of their weaning pups. *J Nutr Sci Vitaminol (Tokyo).* 2008; 54:46–53. [PubMed: 18388407]
39. Naef L, Srivastava L, Gratton A, Hendrickson H, Owens SM, Walker CD. Maternal high fat diet during the perinatal period alters mesocorticolimbic dopamine in the adult rat offspring: reduction in the behavioral responses to repeated amphetamine administration. *Psychopharmacology.* 2008; 197:83–94. [PubMed: 18004547]
40. Naef L, Moquin L, Dal Bo G, Giros B, Gratton A, Walker CD. Maternal high-fat intake alters presynaptic regulation of dopamine in the nucleus accumbens and increases motivation for fat rewards in the offspring. *Neuroscience.* 2011; 176:225–236. [PubMed: 21187125]
41. Grayson BE, Levasseur PR, Williams SM, Smith MS, Marks DL, Grove KL. Changes in melanocortin expression and inflammatory pathways in fetal offspring of nonhuman primates fed a high-fat diet. *Endocrinology.* 2010; 151:1622–1632. [PubMed: 20176722]
42. Leibowitz SF, Akabayashi A, Wang J, Alexander JT, Dourmashkin JT, Chang GQ. Increased caloric intake on a fat-rich diet: role of ovarian steroids and galanin in the medial preoptic and paraventricular nuclei and anterior pituitary of female rats. *Journal of neuroendocrinology.* 2007; 19:753–766. [PubMed: 17850457]
43. Frias AE, Morgan TK, Evans AE, Rasanen J, Oh KY, Thornburg KL, Grove KL. Maternal high-fat diet disturbs uteroplacental hemodynamics and increases the frequency of stillbirth in a nonhuman primate model of excess nutrition. *Endocrinology.* 2011; 152:2456–2464. [PubMed: 21447636]
44. Wallace JM, Milne JS, Matsuzaki M, Aitken RP. Serial measurement of uterine blood flow from mid to late gestation in growth restricted pregnancies induced by overnourishing adolescent sheep dams. *Placenta.* 2008; 29:718–724. [PubMed: 18579200]
45. Taylor PD, Khan IY, Lakasing L, Dekou V, O'Brien-Coker I, Mallet AI, Hanson MA, Poston L. Uterine artery function in pregnant rats fed a diet supplemented with animal lard. *Experimental physiology.* 2003; 88:389–398. [PubMed: 12719763]
46. Das UN. Is obesity an inflammatory condition? *Nutrition.* 2001; 17:953–966. [PubMed: 11744348]
47. Challier JC, Basu S, Bintein T, Minium J, Hotmire K, Catalano PM, Hauguel-de Mouzon S. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta. *Placenta.* 2008; 29:274–281. [PubMed: 18262644]
48. Roberts KA, Riley SC, Reynolds RM, Barr S, Evans M, Statham A, Hor K, Jabbour HN, Norman JE, Denison FC. Placental structure and inflammation in pregnancies associated with obesity. *Placenta.* 2011; 32:247–254. [PubMed: 21232790]
49. Basu S, Haghiac M, Surace P, Challier JC, Guerre-Millo M, Singh K, Waters T, Minium J, Presley L, Catalano PM, Hauguel-de Mouzon S. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. *Obesity (Silver Spring).* 2011; 19:476–482. [PubMed: 20930711]
50. Lassenius MI, Pietilainen KH, Kaartinen K, Pussinen PJ, Syrjanen J, Forsblom C, Porsti I, Rissanen A, Kaprio J, Mustonen J, Groop PH, Lehto M. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. *Diabetes care.* 2011; 34:1809–1815. [PubMed: 21636801]
51. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. *The Journal of biological chemistry.* 1999; 274:10689–10692. [PubMed: 10196138]
52. Stewart FM, Freeman DJ, Ramsay JE, Greer IA, Caslake M, Ferrell WR. Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function throughout pregnancy in lean and obese mothers. *The Journal of clinical endocrinology and metabolism.* 2007; 92:969–975. [PubMed: 17192290]

53. Park CW, Moon KC, Park JS, Jun JK, Yoon BH. The frequency and clinical significance of intra-uterine infection and inflammation in patients with placenta previa and preterm labor and intact membranes. *Placenta*. 2009; 30:613–618. [PubMed: 19447490]
54. Zhu MJ, Du M, Nathanielsz PW, Ford SP. Maternal obesity up-regulates inflammatory signaling pathways and enhances cytokine expression in the mid-gestation sheep placenta. *Placenta*. 2010; 31:387–391. [PubMed: 20185176]
55. Gilmore JH, Jarskog LF, Vadlamudi S. Maternal poly I:C exposure during pregnancy regulates TNF alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat. *Journal of neuroimmunology*. 2005; 159:106–112. [PubMed: 15652408]
56. Urakubo A, Jarskog LF, Lieberman JA, Gilmore JH. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. *Schizophrenia research*. 2001; 47:27–36. [PubMed: 11163542]
57. Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: a critical role for the immune system. *Frontiers in behavioral neuroscience*. 2009; 3:14. [PubMed: 19738918]
58. Bland ST, Beckley JT, Young S, Tsang V, Watkins LR, Maier SF, Bilbo SD. Enduring consequences of early-life infection on glial and neural cell genesis within cognitive regions of the brain. *Brain, behavior, and immunity*. 2010; 24:329–338.
59. Rada P, Barson JR, Leibowitz SF, Hoebel BG. Opioids in the hypothalamus control dopamine and acetylcholine levels in the nucleus accumbens. *Brain research*. 2010; 1312:1–9. [PubMed: 19948154]
60. Barson JR, Morganstern I, Leibowitz SF. Galanin and consummatory behavior: special relationship with dietary fat, alcohol and circulating lipids. *Exs*. 2010; 102:87–111. [PubMed: 21299064]
61. Patterson PH. Maternal infection and immune involvement in autism. *Trends in molecular medicine*. 2011; 17:389–394. [PubMed: 21482187]
62. Kneeland RE, Fatemi SH. Viral infection, inflammation and schizophrenia. *Progress in neuro-psychopharmacology & biological psychiatry*. 2012
63. Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G, Guitart X, Manji HK. Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. *Journal of affective disorders*. 2010; 124:164–169. [PubMed: 19913919]
64. Short SJ, Lubach GR, Karasin AI, Olsen CW, Styner M, Knickmeyer RC, Gilmore JH, Coe CL. Maternal influenza infection during pregnancy impacts postnatal brain development in the rhesus monkey. *Biological psychiatry*. 2010; 67:965–973. [PubMed: 20079486]
65. Chao CC, Ala TA, Hu S, Crossley KB, Sherman RE, Peterson PK, Frey WH 2nd. Serum cytokine levels in patients with Alzheimer's disease. *Clinical and diagnostic laboratory immunology*. 1994; 1:433–436. [PubMed: 8556481]
66. Arranz L, Guayerbas N, De la Fuente M. Impairment of several immune functions in anxious women. *Journal of psychosomatic research*. 2007; 62:1–8. [PubMed: 17188114]
67. Maes M, Song C, Lin A, De Jongh R, Van Gastel A, Kenis G, Bosmans E, De Meester I, Benoy I, Neels H, Demedts P, Janca A, Scharpe S, Smith RS. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. *Cytokine*. 1998; 10:313–318. [PubMed: 9617578]
68. Pitsavos C, Panagiotakos DB, Papageorgiou C, Tsetsekou E, Soldatos C, Stefanadis C. Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. *Atherosclerosis*. 2006; 185:320–326. [PubMed: 16005881]
69. Henje Blom E, Lekander M, Ingvar M, Asberg M, Mobarrez F, Serlachius E. Pro-inflammatory cytokines are elevated in adolescent females with emotional disorders not treated with SSRIs. *Journal of affective disorders*. 2012; 136:716–723. [PubMed: 22056230]
70. Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. *Neuropsychobiology*. 1990; 24:115–120. [PubMed: 2135065]
71. Bob P, Raboch J, Maes M, Susta M, Pavlat J, Jasova D, Vevera J, Uhrova J, Benakova H, Zima T. Depression, traumatic stress and interleukin-6. *Journal of affective disorders*. 2010; 120:231–234. [PubMed: 19359044]

72. Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, Kharrazi M, Ashwood P, Van de Water J. Increased midgestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: A case-control study. *Molecular autism*. 2011; 2:13. [PubMed: 21810230]
73. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Altered T cell responses in children with autism. *Brain, behavior, and immunity*. 2011; 25:840–849.
74. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. *Journal of neuroimmunology*. 2011; 232:196–199. [PubMed: 21095018]
75. Oades RD. An exploration of the associations of pregnancy and perinatal features with cytokines and tryptophan/kynurenine metabolism in children with attention-deficit hyperactivity disorder (ADHD). *Attention deficit and hyperactivity disorders*. 2011; 3:301–318. [PubMed: 21785943]
76. Buehler MR. A proposed mechanism for autism: an aberrant neuroimmune response manifested as a psychiatric disorder. *Medical hypotheses*. 2011; 76:863–870. [PubMed: 21421290]
77. Ellman LM, Deicken RF, Vinogradov S, Kremen WS, Poole JH, Kern DM, Tsai WY, Schaefer CA, Brown AS. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. *Schizophrenia research*. 2010; 121:46–54. [PubMed: 20553865]
78. Willette AA, Lubach GR, Knickmeyer RC, Short SJ, Styner M, Gilmore JH, Coe CL. Brain enlargement and increased behavioral and cytokine reactivity in infant monkeys following acute prenatal endotoxemia. *Behavioural brain research*. 2011; 219:108–115. [PubMed: 21192986]
79. Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. *Molecular psychiatry*. 2006; 11:47–55. [PubMed: 16189509]
80. Osto M, Zini E, Franchini M, Wolfrum C, Guscetti F, Hafner M, Ackermann M, Reusch CE, Lutz TA. Subacute endotoxemia induces adipose inflammation and changes in lipid and lipoprotein metabolism in cats. *Endocrinology*. 2011; 152:804–815. [PubMed: 21266508]
81. Wearn JG, Suagee JK, Crisman MV, Corl BA, Hulver MW, Hodgson DR, Geor RJ, McCutcheon LJ. Effects of the insulin sensitizing drug, pioglitazone, and lipopolysaccharide administration on markers of systemic inflammation and clinical parameters in horses. *Veterinary immunology and immunopathology*. 2012; 145:42–49. [PubMed: 22088672]
82. Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, Kennedy DP, Morgan J. Mapping early brain development in autism. *Neuron*. 2007; 56:399–413. [PubMed: 17964254]
83. Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. *Trends in neurosciences*. 2008; 31:137–145. [PubMed: 18258309]
84. Lu J, Wu DM, Zheng YL, Hu B, Cheng W, Zhang ZF, Shan Q. Ursolic acid improves high fat diet-induced cognitive impairments by blocking endoplasmic reticulum stress and I κ B kinase beta/nuclear factor-kappaB-mediated inflammatory pathways in mice. *Brain, behavior, and immunity*. 2011; 25:1658–1667.
85. Leung GM, Lam KS. Diabetic complications and their implications on health care in Asia. *Hong Kong medical journal = Xianggang yi xue za zhi/Hong Kong Academy of Medicine*. 2000; 6:61–68. [PubMed: 10793404]
86. Radaelli T, Varastehpour A, Catalano P, Hauguel-de Mouzon S. Gestational diabetes induces placental genes for chronic stress and inflammatory pathways. *Diabetes*. 2003; 52:2951–2958. [PubMed: 14633856]
87. Vambergue A, Fajardy I. Consequences of gestational and pregestational diabetes on placental function and birth weight. *World journal of diabetes*. 2011; 2:196–203. [PubMed: 22087356]
88. Leung TW, Lao TT. Placental size and large-for-gestational-age infants in women with abnormal glucose tolerance in pregnancy. *Diabetic medicine: a journal of the British Diabetic Association*. 2000; 17:48–52. [PubMed: 10691159]
89. Oken E, Gillman MW. Fetal origins of obesity. *Obes Res*. 2003; 11:496–506. [PubMed: 12690076]
90. Simerly RB. Hypothalamic substrates of metabolic imprinting. *Physiol Behav*. 2008; 94:79–89. [PubMed: 18262209]

91. Jones AP, Pothos EN, Rada P, Olster DH, Hoebel BG. Maternal hormonal manipulations in rats cause obesity and increase medial hypothalamic norepinephrine release in male offspring. *Brain research Developmental brain research*. 1995; 88:127–131. [PubMed: 8665659]
92. Jones AP, Dayries M. Maternal hormone manipulations and the development of obesity in rats. *Physiology & behavior*. 1990; 47:1107–1110. [PubMed: 2204072]
93. Plagemann A, Heidrich I, Götz F, Rohde W, Dorner G. Lifelong enhanced diabetes susceptibility and obesity after temporary intrahypothalamic hyperinsulinism during brain organization. *Exp Clin Endocrinol*. 1992; 99:91–95. [PubMed: 1639125]
94. Djiane J, Attig L. Role of leptin during perinatal metabolic programming and obesity. *J Physiol Pharmacol*. 2008; 59(Suppl 1):55–63. [PubMed: 18802216]
95. Bouret SG. Development of hypothalamic neural networks controlling appetite. *Forum Nutr*. 2010; 63:84–93. [PubMed: 19955776]
96. Kirk SL, Samuelsson AM, Argenton M, Dhonye H, Kalamatianos T, Poston L, Taylor PD, Coen CW. Maternal obesity induced by diet in rats permanently influences central processes regulating food intake in offspring. *PloS one*. 2009; 4:e5870. [PubMed: 19516909]
97. Glavas MM, Kirigiti MA, Xiao XQ, Enriori PJ, Fisher SK, Evans AE, Grayson BE, Cowley MA, Smith MS, Grove KL. Early overnutrition results in early-onset arcuate leptin resistance and increased sensitivity to high-fat diet. *Endocrinology*. 2010; 151:1598–1610. [PubMed: 20194730]
98. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. *American journal of obstetrics and gynecology*. 2002; 187:127–136. [PubMed: 12114900]
99. Hauguel-de Mouzon S, Lepercq J, Catalano P. The known and unknown of leptin in pregnancy. *American journal of obstetrics and gynecology*. 2006; 194:1537–1545. [PubMed: 16731069]
100. Lepercq J, Guerre-Millo M, Andre J, Cauzac M, Hauguel-de Mouzon S. Leptin: a potential marker of placental insufficiency. *Gynecologic and obstetric investigation*. 2003; 55:151–155. [PubMed: 12865594]
101. Jaquet D, Leger J, Levy-Marchal C, Oury JF, Czernichow P. Ontogeny of leptin in human fetuses and newborns: effect of intrauterine growth retardation on serum leptin concentrations. *The Journal of clinical endocrinology and metabolism*. 1998; 83:1243–1246. [PubMed: 9543149]
102. Davidowa H, Plagemann A. Decreased inhibition by leptin of hypothalamic arcuate neurons in neonatally overfed young rats. *Neuroreport*. 2000; 11:2795–2798. [PubMed: 10976965]
103. Grayson BE, Allen SE, Billes SK, Williams SM, Smith MS, Grove KL. Prenatal development of hypothalamic neuropeptide systems in the nonhuman primate. *Neuroscience*. 2006; 143:975–986. [PubMed: 17029798]
104. Grayson BE, Kievit P, Smith MS, Grove KL. Critical determinants of hypothalamic appetitive neuropeptide development and expression: species considerations. *Frontiers in neuroendocrinology*. 2010; 31:16–31. [PubMed: 19822169]
105. Figlewicz DP, Higgins MS, Ng-Evans SB, Havel PJ. Leptin reverses sucrose-conditioned place preference in food-restricted rats. *Physiology & behavior*. 2001; 73:229–234. [PubMed: 11399316]
106. Figlewicz DP, Bennett J, Evans SB, Kaiyala K, Sipols AJ, Benoit SC. Intraventricular insulin and leptin reverse place preference conditioned with high-fat diet in rats. *Behavioral neuroscience*. 2004; 118:479–487. [PubMed: 15174925]
107. Kannan S, Saadani-Makki F, Balakrishnan B, Dai H, Chakraborty PK, Janisse J, Muzik O, Romero R, Chugani DC. Decreased cortical serotonin in neonatal rabbits exposed to endotoxin in utero. *J Cereb Blood Flow Metab*. 2011; 31:738–749. [PubMed: 20827261]
108. Daws LC, Gould GG. Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. *Pharmacol Ther*. 2011; 131:61–79. [PubMed: 21447358]
109. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. *Science*. 1998; 281:1191–1193. [PubMed: 9712583]
110. Ligam P, Manuelpillai U, Wallace EM, Walker D. Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy. *Placenta*. 2005; 26:498–504. [PubMed: 15950064]

111. Pfaff AW, Mousli M, Senegas A, Marcellin L, Takikawa O, Klein JP, Candolfi E. Impact of foetus and mother on IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase expression in murine placenta following *Toxoplasma gondii* infection. *Int J Parasitol.* 2008; 38:249–258. [PubMed: 17822706]
112. Kiyohara C, Yoshimasu K. Molecular epidemiology of major depressive disorder. *Environ Health Prev Med.* 2009; 14:71–87. [PubMed: 19568851]
113. Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. *The American journal of psychiatry.* 1996; 153:174–182. [PubMed: 8561196]
114. Oades RD, Lasky-Su J, Christiansen H, Faraone SV, Sonuga-Barke EJ, Banaschewski T, Chen W, Anney RJ, Buitelaar JK, Ebstein RP, Franke B, Gill M, Miranda A, Roeyers H, Rothenberger A, Sergeant JA, Steinhausen HC, Taylor EA, Thompson M, Asherson P. The influence of serotonin- and other genes on impulsive behavioral aggression and cognitive impulsivity in children with attention-deficit/hyperactivity disorder (ADHD): Findings from a family-based association test (FBAT) analysis. *Behav Brain Funct.* 2008; 4:48. [PubMed: 18937842]
115. Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. *Ann Neurol.* 1999; 45:287–295. [PubMed: 10072042]